The research context establishes that autophagic pathways compete for limited ATG machinery in aging endothelium, with oxidized lipids hijacking priority away from mitophagy [doi.org/10.1016/j.ajpath.2013.04.028]. This is a critical insight, but it's incomplete. It treats hierarchy as a static resource allocation problem—like a budget overrun—where lipophagy and ER-phagy simply outspend mitophagy. The mechanistic gap is time. Autophagic selectivity isn't just a priority list; it's a temporally encoded sequence. We propose that healthy vascular endothelium maintains a strict "triage timer": a rapid, initial wave of mitophagy to clear oxidative damage, followed by a slower, sustained phase of ER-phagy/lipophagy for remodeling. Aging and oxidized lipids don't just alter the priority—they corrupt the timer, desynchronizing the sequence and creating pathological interference between pathways.

Here's the novel mechanism: The initiation machinery (ULK1 complex, phagophore formation) is the shared, rate-limiting bottleneck. In youth, mitophagy receptors like FUNDC1 or BNIP3L have higher affinity or are pre-positioned to "claim" nascent autophagosomes first, creating a temporal dominance window for mitochondrial clearance. Oxidized lipids, particularly 7-ketocholesterol, alter this by directly modifying the activity of key ATG proteins [doi.org/10.1016/j.ajpath.2013.04.028]. Our hypothesis centers on Atg4B, the protease that processes LC3 and is inhibited by lipid-induced H₂O₂. We propose Atg4B inhibition doesn't just blunt autophagy globally; it slows the lipidation cycle of LC3. This creates a bottleneck at autophagosome formation, disproportionately harming fast-responding, high-turnover processes like mitophagy while slower, constitutive processes like lipophagy eventually compensate. The "timer" is the LC3 lipidation turnover rate, and it's being deliberately slowed, skewing the temporal sequence.

Falsifiable Predictions:

1. Temporal Sequencing Biomarker: In young endothelial cells, a pulse of oxidative stress will induce a measurable peak in mitophagy (e.g., via mt-Keima flux) within 1-2 hours, followed by a secondary peak in ER-phagy (FAM134B puncta) at 4-6 hours. This sequence will be flattened or reversed in cells from aged vessels or treated with 7-ketocholesterol.
2. Atg4B Kinetics Over Expression: The key dysfunction isn't low Atg4B levels, but its activity kinetics. Measuring the rate of LC3-I to LC3-II conversion in real-time (using pulse-chase assays with tagged LC3) will show a markedly slower turnover rate in aged endothelium, correlating with arterial stiffness (PWV) more strongly than static levels of autophagy proteins.
3. Rescue via Temporal Bypass: Simply overexpressing TFEB to boost all autophagy [doi.org/10.1038/ncomms15750] will be less effective in restoring endothelial function than targeted interventions that accelerate the initial mitophagy phase. For example, administering a mitochondrial-targeted autophagy inducer (like a specific peptide agonist of BNIP3L) before a global autophagy stimulus like trehalose should restore proper sequence and improve NO production more effectively than simultaneous administration. This tests if re-establishing the temporal order is more critical than total flux.

This model shifts the therapeutic goal from "boost autophagy" to "re-synchronize the autophagic triage timer." The hierarchy isn't just broken—it's out of time.